Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Spire Wealth Management

Spire Wealth Management lifted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1,342.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,429 shares of the biopharmaceutical company's stock after purchasing an additional 13,429 shares during the period. Spire Wealth Management's holdings in Catalyst Pharmaceuticals were worth $301,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CPRX. GAMMA Investing LLC lifted its position in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 681 shares during the last quarter. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the third quarter valued at $50,000. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 2,994 shares during the last quarter. KBC Group NV boosted its position in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalyst Pharmaceuticals during the 4th quarter worth about $134,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock traded down $0.14 during midday trading on Monday, hitting $22.76. 763,037 shares of the company's stock were exchanged, compared to its average volume of 1,355,897. The firm's 50 day simple moving average is $22.09 and its 200 day simple moving average is $20.99. Catalyst Pharmaceuticals, Inc. has a 12-month low of $13.13 and a 12-month high of $24.64. The stock has a market cap of $2.71 billion, a price-to-earnings ratio of 19.29, a price-to-earnings-growth ratio of 3.46 and a beta of 0.80.

Insider Buying and Selling

In related news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Molly Harper sold 17,500 shares of the company's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock valued at $1,754,140 over the last quarter. 11.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Bank of America restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 target price on the stock. HC Wainwright boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Finally, Robert W. Baird initiated coverage on Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They set an "outperform" rating and a $28.00 price objective on the stock. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $32.25.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.